Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term
management to optimise patient outcomes. The Pituitary Society convened a consensus …

Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …

Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Gastrointestinal neuroendocrine tumors are rare slow-growing tumors with distinct
histological, biological, and clinical characteristics that have increased in incidence and …

Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the
past decades, and are now the most common type of small bowel tumor. Consequently …

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …

Currently, different radiometals are in use for imaging and therapy in nuclear medicine:
68Ga and 111In are examples of nuclides for positron emission tomography (PET) and …

This study aimed to assess the clinical impact of 68Ga-DOTATATE and 18F-FDG with
respect to the management plan and to evaluate the prognostic value of both tracers …

The high affinity and specificity of peptides towards biological targets, in addition to their
favorable pharmacological properties, has encouraged the development of many peptide …